TY - JOUR
T1 - A case of hepatic resection after chemotherapy for metastatic colon cancer of the liver with invasion of the inferior vena cava and hepatic vein
AU - Komatsu, Hisateru
AU - Tomokuni, Akira
AU - Wada, Hiroshi
AU - Kobayashi, Shogo
AU - Tomimaru, Yoshito
AU - Asaoka, Tadafumi
AU - Hama, Naoki
AU - Kawamoto, Koichi
AU - Marubashi, Shigeru
AU - Eguchi, Hidetoshi
AU - Umeshita, Koji
AU - Doki, Yuichiro
AU - Mori, Masaki
AU - Nagano, Hiroaki
PY - 2014/11
Y1 - 2014/11
N2 - A 61-year-old man presented with lower abdominal pain. Further examination revealed descending colon cancer and multiple liver metastases (S1, S2, and S5). The largest metastatic lesion in S1 showed massive invasion to the inferior vena cava (IVC) and was considered unresectable. Resection of the primary colon cancer was performed in January 2011, followed by several types of systemic chemotherapy (12 courses of capecitabine plus oxaliplatin [XELOX] +bevacizumab [Response Evaluation Criteria In Solid Tumors {RECIST}: PD], 5 courses of folinic acid, fluorouracil, and irinotecan [FOLFIRI] + bevacizumab [RECIST: SD], and 13 courses of FOLFIRI + panitumumab). After these regimens, the lesions in S1 and S2 substantially decreased in size (RECIST: PR), and the lesion in S5 was no longer visible. The extent of invasion to the IVC significantly reduced, and liver resection (extended left lobectomy) and partial IVC resection were performed in November 2013 without reconstruction of the IVC by using a vascular prosthesis. The patient was discharged uneventfully on postoperative day 16, and administration of tegafur-uracil-Leucovorin (UFT/UZEL) was initiated. After 4 months, a recurrent lesion was found in S5, and partial liver resection was performed. In addition, FOLFIRI+panitumumab was reinitiated for the multiple lung metastases. The patient is alive without progression of disease 3 years and 4 months after colectomy.
AB - A 61-year-old man presented with lower abdominal pain. Further examination revealed descending colon cancer and multiple liver metastases (S1, S2, and S5). The largest metastatic lesion in S1 showed massive invasion to the inferior vena cava (IVC) and was considered unresectable. Resection of the primary colon cancer was performed in January 2011, followed by several types of systemic chemotherapy (12 courses of capecitabine plus oxaliplatin [XELOX] +bevacizumab [Response Evaluation Criteria In Solid Tumors {RECIST}: PD], 5 courses of folinic acid, fluorouracil, and irinotecan [FOLFIRI] + bevacizumab [RECIST: SD], and 13 courses of FOLFIRI + panitumumab). After these regimens, the lesions in S1 and S2 substantially decreased in size (RECIST: PR), and the lesion in S5 was no longer visible. The extent of invasion to the IVC significantly reduced, and liver resection (extended left lobectomy) and partial IVC resection were performed in November 2013 without reconstruction of the IVC by using a vascular prosthesis. The patient was discharged uneventfully on postoperative day 16, and administration of tegafur-uracil-Leucovorin (UFT/UZEL) was initiated. After 4 months, a recurrent lesion was found in S5, and partial liver resection was performed. In addition, FOLFIRI+panitumumab was reinitiated for the multiple lung metastases. The patient is alive without progression of disease 3 years and 4 months after colectomy.
UR - http://www.scopus.com/inward/record.url?scp=84949202000&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949202000&partnerID=8YFLogxK
M3 - Article
C2 - 25731422
AN - SCOPUS:84949202000
SN - 0385-0684
VL - 41
SP - 2059
EP - 2061
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
IS - 12
ER -